Efficacy Without Tolerance or Rebound Insomnia for Midazolam and Temazepam After Use for One to Three Months

Richard P. Allen, Joseph Mendels, Donald B. Nevins, Doris A. Chernik, Eric Hoddes

Research output: Contribution to journalArticle

Abstract

Midazolam (15 mg) was compared with temazepam (30 mg) in a randomized, double‐blind, parallel group study. An initial screening period was followed by 3 days of placebo baseline, 4 to 12 weeks of nightly oral use of the medication and a 4‐day placebo withdrawal period. One hundred seventy‐five patients with chronic insomnia participated in this multicenter outpatient study. Because the elimination half‐life of midazolam, a new trizolobenzodiazepine hypnotic, is short (1.3‐2.2 hr) compared to temazepam's (12–16 hr), more problems with tolerance and rebound insomnia were expected to occur. Hypnotic efficacy (increased total sleep time, decreased wake time, and decreased sleep latency) was demonstrated for both medications over the entire 3‐month period without the development of tolerance, In fact, if anything, efficacy increased with time on medication, suggesting possible facilitation or “inverse tolerance” effect. On withdrawal, sleep was improved compared with baseline, suggesting partial resolution of the insomniac condition rather than rebound insomnia. These effects were both statistically and clinically significant for midazolam, with 16% to 50% improvement in sleep measures. The results of this study suggest that patients with chronic insomnia may benefit from 30 to 90 days of treatment. A three‐factor model that separates pharmacologic from behavioral and psychologic effects of hypnotics was proposed to explain these results in part. 1987 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)768-775
Number of pages8
JournalThe Journal of Clinical Pharmacology
Volume27
Issue number10
DOIs
StatePublished - Oct 1987

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Efficacy Without Tolerance or Rebound Insomnia for Midazolam and Temazepam After Use for One to Three Months'. Together they form a unique fingerprint.

  • Cite this